Equitable fraud exception
81 Also raised in exchanges on the day before the hearing and at the hearing was an argument that the fraud exception for privilege would apply to a number of documents. After the hearing, Admedus Limited and Admedus Australia responded to the plaintiffs' belated challenge and further category of documents based on the concept of 'equitable fraud'. Those documents were listed in the schedule handed to the Court during the hearing. The category comprises 27 documents. On this topic, the plaintiffs had referred to AWB (at [210]-[217]) to support an argument that the fraud exception applied so that there could be no claim of privilege in relation to the documents. Young J there observed (at [217]) that '… there must be more than a mere assertion or allegation of fraud or impropriety.' In that case, however, Young J held that the relevant documents under consideration were prima facie brought into existence in furtherance of or as a step preparatory to an improper or dishonest purpose, in that, prima facie, the evidence established that the transaction was deliberately and dishonestly structured so as to misrepresent the true nature and purpose of certain fees and to 'work a trickery'. Justice North also considered the circumstances on which the fraud exception would apply and considered the authorities in Clements, Dunne and Bell Pty Ltd v Commissioner, Australian Federal Police [2001] FCA 1858 (at [40]-[41]) where his Honour said:
40 In Propend Brennan J said, at 514:
"In determining whether a claim of legal professional privilege can be upheld, it is open to the party resisting the claim to show reasonable grounds for believing that the communication effected by the document for which legal professional privilege is claimed was made for some illegal or improper purpose, that is, some purpose that is contrary to the public interest."
41 Gummow J described the scope of this limitation, at 563-564 as follows:
"[T]he privilege does not attach to a communication made as part of a criminal or unlawful proceeding or in furtherance of an illegal object. The privilege would not attach where the plaintiff sought legal assistance as a step in, or preparatory to, the commission of a crime or fraud, even though the solicitor was unaware of the purpose of the communication at the time it was made [R v Bell; Ex parte Lees (1980) 146 CLR 141 at 145]. The communication would still be 'designed to facilitate future wrongdoing' [Carter v Managing Partner Northmore Hale Davy & Leake (1995) 183 CLR 121 at 163]. In addition, the privilege does not protect communications made to further a deliberate abuse of statutory power and by that abuse to prevent others from exercising their rights under the law [Attorney-General (NT) v Kearney (1985) 158 CLR 580]. It follows that the operation of the privilege is not decided, as a general proposition, merely by a determination in the instant proceeding of whether facts amounting to a crime have been proved. The nature of the alleged impropriety and thus the issue of existence of the privilege will vary from case to case."
82 There is no allegation of fraud pleaded in this matter. The allegations are to the effect that actions have been taken in conflict of duties owed to Admedus Regen. It is not possible to be satisfied 'with sufficient probability of its truth to make it right to disallow the privilege claim'. The plaintiffs seek to support their claim by a very last minute argument, referring to a few lines in some document and with no amplification of the surrounding circumstances. Such a serious claim cannot be proven in this way.
83 In further reply submissions, the plaintiffs reject any flimsiness in their claim, and seek to establish the claim by reference to the following:
6.1 the minutes of the board meeting of the first defendant, held on 15 August 2012
Manufacturing scale-up is being planned and will need to be pushed forward when funds allow.
The appointment of the VP Operations has been put on hold until further funding has been secured. They will be instrumental in pushing forward the scale-up of our Manufacturing capabilities.
…
The role of VP Operation for Celxcel was to be offered to Helen Wray is currently on hold in line with Forecast 2012/13. This is an essential appointment to enable robust scale-up of manufacturing and processes. Lane affidavit, 7 November 2014, pp.311 (sub nom. "Commercial Activities") and 316 (sub nom. "6.2 Staffing");
6.2 the board report of the first defendant's CEO, Bob Atwill, dated 10 April 2013:
THE KEY GOALS AND FOCUS REMAIN
…
• Planning and implementing manufacturing scale up of Cardiocel,
…
MANUFACTURING, SCALE UP & LAB
…
• Commissioning of owned facilities is under discussion with Biotech Corporation ... EDB ... and with Sanofi/Genzyme. This process will take 18 months to 2 years and is why we need to also undertake the CMO [contract manufacturing] route as well.
• We will be hiring a production manager as soon as we have chosen where we will be manufacturing. (Emphasis added).
Lane affidavit, 7 November 2014, pp.594-5. The first defendant was thus holding discussions with 3 entities for the purchase of manufacturing facilities. One of those was the Sanofi/Genzyme Group, from which the second defendant purchased Admedus Bio. Although pleaded with some obfuscation in relation to which entities the relevant representatives of the first defendant were representing at material times, the second and third defendants admit that (a) the first defendant needed to scale up the manufacturing of CardioCel®; (b) the first defendant had employed Wray to implement those plans; (c) Wray, the Vice President of Operations of the first defendant, was the person who first approached Admedus Bio (then named Verigen); and (d) Wray then introduced Atwill and Rodne, directors of the first defendant, to representatives of the Sanofi Group; FASOC, [55]-[57], [60]; Amended Defence, [44]-[46], [49]. Most of the allegations in the Amended Defence in relation to this issue are gainsaid by the knowledge of the first defendant's CEO, at 10 April 2013, (6.2 above) which was communicated to the other directors, including Rodne.
6.3 the draft minutes of the board meeting of the first defendant, held on 12 June 2013:
The Sanofi Perth facility is caught up in a potential sale of one of their whole divisions but we've been invited to submit an expression of interest (EOI) on acquiring this facility which we're in process of doing by the 14th of June.
Lane affidavit, 7 November 2014, p.600 (sub nom. "Manufacturing, Scale-up & Lab"). This was consistent with the board report of the first defendant's CEO, referred to in 6.2 above; and
6.4 the second defendant's ASX announcement, dated 12 December 2013, that Admedus Bio had been purchased "to facilitate scale-up production of ... CardioCel®" and that it allowed "Admedus to accelerate its manufacturing capabilities in anticipation of growing CardioCel® sales ... ", precisely the plan and business of the first defendant.
7. The real defence of the second and third defendants in relation to the acquisition of Admedus Bio appears to be that the first defendant did not have the financial capacity to acquire Admedus Bio, which is bad in law; Streeter v Western Areas Exploration Pty Ltd [no 2] [2011] WASCA 17 at [64], [367], [369], [379], [381 ]-[385]; [397]-[399], [487] and the cases referred to therein. No particulars were provided of the first defendant's financial capacity or the actual cost of the acquisition of the shares in Admedus Bio; cf Reply, at [4].
8. In relation to the Distribution Agreement, the allegations as to breach of fiduciary duty by 2 of the directors of the first defendant, Rodne and Atwill, and the manifest uncommerciality of the terms of the Distribution Agreement, which were heavily skewed in favour of the second and third defendants, speak for themselves. Significantly, the second and third defendants have withdrawn their defence that the terms of the Distribution Agreement were "in accordance with industry standards"; FASOC, [41]-[54]; Amended Defence, [35(i)] (deleted), [43(b)(iii)] (deleted).
84 The second and third defendants contend (by email) that the material relied upon by the plaintiffs to support the claim is incomplete and inaccurate. The defendants assert as follows:
2 Para. 6.1: The quote is referred to out of context. The preceding paragraph reads
"Discussion with potential contract manufacturers have progressed with Sydney Cell and Gene Therapy, Genzyme/Verigen facility WA, QIMR Qld Lonza in Singapore. At this stage others are still being contacted as well."
3 Para. 6.2: This misquotes documents or omits information:
(a) see paras. 44(a)(i) and 44(a)(iii)(A) of the Second and Third Defendants' Amended Defence filed on 31 July 2015 (Amended Defence);
(b) para. 46(b)(i) of the Amended Defence refers specifically to contract manufacturing, not to the purchase of manufacturing facilities;
(c) the omitted sentences set out in para. 2 above demonstrate that the First Defendant was in discussions with 3 entities about contract manufacturing, not the purchase of manufacturing facilities; and
(d) in para. 3 of the Plaintiffs' Reply to the Second and Third Defendants' Defence and Defence to Cross Claim filed on 17 April 2015, the Plaintiffs plead a positive case that Helen Wray was employed by the Second Defendant; this is inconsistent with their submission that Ms Wray was employed by the First Defendant.
4 Para. 6.3 refers to draft board minutes. The Second and Third Defendants rely on the final signed minutes of the First Defendant's board meeting held on 12 June 2013, as set out in the particulars to para. 51(d) of the Amended Defence. The final signed minutes record that Sanofi invited the Second Defendant, not the First Defendant, to submit an expression of interest.
5 Para 7: the Amended Defence is not limited to the lack of financial capacity of the First Defendant to acquire Admedus Bio. Paras. 51 to 53 of the Amended Defence plead that the Second Defendant was invited by Sanofi to submit an expression of interest to purchase the entire Cell Therapy business, and was approached again by Sanofi in September 2013 to purchase Admedus Bio. The particulars to paras. 50(a}, 50(b), 76 and 90 of the Amended Defence particularise the First Defendant's financial capacity. The cost of the acquisition is also set out in the particulars to para. 50(a) of the Amended Defence.
85 Absent more complete evidence as to the context in which the statements in the documents were made, it is not possible to determine which, if either, account by the parties is correct. What can be said is that the small amount of information referred to very late in the piece on this application falls well short of setting up an enquiry as to the existence of the fraud exception and any consequent waiver of privilege.
86 As indicated above, I do not propose to reach any conclusion in favour of the plaintiffs' assertion that any claim for privilege should be eroded on the basis of equitable fraud. Numerous communications were exchanged prior to the hearing of this application and including letters, emails and submissions. The topic was raised as a last minute thought, apparently in a further communication on the day preceding the hearing. Quite properly, the defendants objected to the plaintiffs' reliance upon it at the hearing. No fraud has been pleaded by the plaintiffs. The foundation for the argument is not only flimsy but has been pursued far too late in the piece. The plaintiffs' contentions on this ground cannot succeed.